# GNPX catalysts: Genprex, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/gnpx/catalysts

> Genprex, Inc. (GNPX) has no upcoming catalysts in this calendar. The latest recorded is the Genprex, Inc. interim data readout, late 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Genprex, Inc. |
| Ticker | GNPX (Nasdaq) |
| SEC CIK | 1595248 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/gnpx |

## Cash runway

Cash $15.3M as of 2026-09-30; quarterly burn $2.9M; about 15.7 months of runway at that rate (XBRL company facts, accession 0001437749-26-036882).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2024 | [Tagrisso® (osimertinib) trial start](https://sec-api.dev/pdufa/osimertinib) | GNPX |  | completed | "Genprex opened the Phase 2a expansion portion of the study and enrolled and dosed the first patient in January 2024." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1595248/000143774925020102/gnpx20250606c_8k.htm)) |
| Jan 2024 | [Tecentriq® (atezolizumab) trial start](https://sec-api.dev/pdufa/atezolizumab) | GNPX |  | completed | "In January 2024, the Company opened the Phase 1 portion of the Acclaim-3 study for enrollment and enrolled and dosed the first patient in May 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1595248/000143774924034697/gnpx20240930_10q.htm)) |
| 1H 2025 | [Genprex, Inc. interim data readout](https://sec-api.dev/companies/gnpx/catalysts) | GNPX |  | scheduled | "The Company expects to complete the enrollment of the first 19 patients for interim analysis in the Phase 2a expansion portion of the study in the first half of 2025 and expects the interim analyses in the second half of 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1595248/000143774925000932/gnpx20250105_8k.htm)) |
| 2H 2025 | [Tecentriq® (atezolizumab) interim data readout](https://sec-api.dev/pdufa/atezolizumab) | GNPX |  | scheduled | "The Company expects to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study in the second half of 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1595248/000143774925000932/gnpx20250105_8k.htm)) |
| 1H 2026 | [GPX-002 interim data readout](https://sec-api.dev/pdufa/gpx-002) | GNPX |  | scheduled | "The Company expects to complete the enrollment of the first 19 patients for interim analysis in the Phase 2a expansion portion of the study in the first half of 2026 and expects the interim analysis in the second half of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/gnpx20251001_8k.htm)) |
| Q1 2026 | [Genprex, Inc. interim data readout](https://sec-api.dev/companies/gnpx/catalysts) | GNPX |  | scheduled | "The Company expects to complete the enrollment of the first 19 patients for interim analysis in the Phase 2a expansion portion of the study by the first quarter of 2026 and expects the interim analysis in the first half of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1595248/000143774925020102/gnpx20250606c_8k.htm)) |
| Q1 2026 | [Genprex, Inc. interim data readout](https://sec-api.dev/companies/gnpx/catalysts) | GNPX |  | scheduled | "We expect to complete the Phase 2 expansion enrollment needed for interim analysis (19 patients) by the end of the first quarter of 2026, and thus we expect to report on our interim analysis in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1595248/000143774925024487/ex_832410.htm)) |
| 1H 2026 | [Tecentriq® (atezolizumab) interim data readout](https://sec-api.dev/pdufa/atezolizumab) | GNPX |  | scheduled | "The Company expects to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study in the first half of 2026 and expects the interim analysis in the second half of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1595248/000143774926004954/gnpx20260220_8k.htm)) |
| late 2026 | [Genprex, Inc. interim data readout](https://sec-api.dev/companies/gnpx/catalysts) | GNPX |  | scheduled | "We expect to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study by the end of 2026 and expect the interim analysis in the first half of 2027." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1595248/000143774926023480/gnpx20260630_8k.htm)) |

## Drugs

- [GPX-002](https://sec-api.dev/pdufa/gpx-002): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/gnpx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GNPX catalysts: Genprex, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/gnpx/catalysts

```bibtex
@misc{secapidev_companies_gnpx_catalysts_20261116,
  title        = {GNPX catalysts: Genprex, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/gnpx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_gnpx_catalysts_20261116","title":"GNPX catalysts: Genprex, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/gnpx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
